サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：外陰カンジダ症治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023～2030年の予測
市場調査レポート
商品コード
1342780

外陰カンジダ症治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023～2030年の予測

Global Vulvovaginal Candidiasis Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日: | 発行: Value Market Research | ページ情報: 英文 177 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
外陰カンジダ症治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023～2030年の予測
出版日: 2023年08月01日
発行: Value Market Research
ページ情報: 英文 177 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

外陰カンジダ症治療市場の世界需要は、調査期間2023～2030年のCAGR6.51%で、2022年の42億米ドルから2030年には約69億6,000万米ドルの市場規模に達すると推定されます。

外陰カンジダ症治療は、一般的な真菌感染症である膣イースト菌感染症の治療です。かゆみ、尿や性交時の灼熱感や不快感、腫れ、発疹、炎症はすべて膣イースト菌感染の徴候です。糖尿病患者の増加や抗生物質の使用頻度の増加に伴い、外陰膣カンジダ症の有病率は増加しています。膣カンジダ症の治療には通常、抗真菌薬が推奨されます。

市場力学：

外陰腟カンジダ症感染症の増加と、その治療に有効な医薬品の必要性から、市場は成長傾向をたどるものと予測されます。研究開発、新薬承認、製品上市の大幅な増加は、より良い治療オプションへの需要を拡大し、外陰カンジダ症治療の商業的成長にとって有益な機会を生み出しています。さらに、ヘルスケアおよび政府投資の増加、ヘルスケアシステムの発展、薬剤の入手しやすさ、製薬およびバイオテクノロジー部門における著しい技術開発のため、予想される期間中、外陰膣カンジダ症治療には多くの機会があります。外陰膣カンジダ症治療市場は、一般市民の認識不足、新技術採用の専門知識、診断・治療法に関連する高コストのために阻害されると推定されます。

調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは外陰カンジダ症治療の世界市場における各セグメントを包括的に評価することもできます。外陰カンジダ症治療産業の成長と動向は、この研究に全体的なアプローチを提供します。

地域分析：

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東＆アフリカにわたる外陰カンジダ症治療市場の現在および将来の需要を強調する地域展望をカバーしています。さらに、本レポートは、すべての主要地域における個々のアプリケーションセグメントの需要、推定・予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 外陰カンジダ症治療- 産業分析

  • イントロダクション-市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 COVID-19発生の影響分析

  • COVID-19発生の影響分析
    • 生産への直接的影響
    • サプライチェーンと市場の混乱
    • 企業および金融市場への財務的影響
  • COVID-19の生産、輸入、輸出、需要による影響分析
  • 市場COVID-19以前／以後
  • コロナウイルス（COVID-19）流行の影響予測
  • COVID-19：ミクロおよびマクロ要因分析

第6章 外陰カンジダ症治療の世界市場分析：薬剤クラス別

  • 薬剤クラス別概要
  • 実績データと予測データ
  • 薬剤クラス別分析
  • クロトリマゾール
  • ナイスタチン
  • フルコナゾール
  • ケトコナゾール
  • テルビナフィン
  • テルコナゾール
  • その他

第7章 外陰カンジダ症治療の世界市場分析：投与経路別

  • 投与経路別概要
  • 実績データと予測データ
  • 投与経路別分析
  • 経口
  • 静脈内投与
  • 局所

第8章 外陰カンジダ症治療の世界市場売上分析：流通チャネル別

  • 流通チャネル別概要
  • 実績データと予測データ
  • 流通チャネル別分析
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第9章 外陰カンジダ症治療の世界市場売上分析：地域別

  • 地域別展望販売分析
  • イントロダクション売上分析
  • 北米売上分析
    • 概要、実績と予測
    • 北米セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • その他アジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ

第10章 外陰カンジダ症治療企業の競合情勢

  • 外陰カンジダ症治療市場競争
  • 提携/協力/合意
  • 合併・買収
  • 新製品の発売
  • その他の開発

第11章 企業プロファイル

  • 上位10社のシェア分析
  • 市場集中度
  • Astellas Pharma Inc.
  • Mycovia Pharmaceuticals Inc.
  • Bayer AG.
  • Basilea Pharmaceutica Ltd.
  • Scynexis Inc.
  • Grupo Ferrer Internacional S.A.
  • Pfizer Inc.
  • Cadila Pharmaceuticals
  • Bristol-Myers Squibb Company
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • COVID-19 Impact Analysis by Production, Import, Export and Demand
  • Pre V/S Post COVID-19
  • Estimated Impact Of The Coronavirus (Covid-19) Epidemic
  • COVID-19: Micro and Macro Factor Analysis
  • Analysis by Drug Class (USD MN)
  • Clotrimazole Market Sales by Geography (USD MN)
  • Nystatin Market Sales by Geography (USD MN)
  • Fluconazole Market Sales by Geography (USD MN)
  • Ketoconazole Market Sales by Geography (USD MN)
  • Terbinafine Market Sales by Geography (USD MN)
  • Terconazole Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis Market by Route Of Administration (USD MN)
  • Oral Market Sales by Geography (USD MN)
  • Intravenous Market Sales by Geography (USD MN)
  • Topical Market Sales by Geography (USD MN)
  • Analysis by Distribution Channel (USD MN)
  • Hospital Pharmacy Market Sales by Geography (USD MN)
  • Retail Pharmacy Market Sales by Geography (USD MN)
  • Online Pharmacy Market Sales by Geography (USD MN)
  • Global Vulvovaginal Candidiasis Treatment Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Vulvovaginal Candidiasis Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Vulvovaginal Candidiasis Treatment Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Drug Class
  • Market Attractiveness Analysis by Route Of Administration
  • Market Attractiveness Analysis by Distribution Channel
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Drug Class (USD MN)
  • Clotrimazole Market Sales by Geography (USD MN)
  • Nystatin Market Sales by Geography (USD MN)
  • Fluconazole Market Sales by Geography (USD MN)
  • Ketoconazole Market Sales by Geography (USD MN)
  • Terbinafine Market Sales by Geography (USD MN)
  • Terconazole Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Route Of Administration (USD MN)
  • Oral Market Sales by Geography (USD MN)
  • Intravenous Market Sales by Geography (USD MN)
  • Topical Market Sales by Geography (USD MN)
  • Global Market Analysis by Distribution Channel (USD MN)
  • Hospital Pharmacy Market Sales by Geography (USD MN)
  • Retail Pharmacy Market Sales by Geography (USD MN)
  • Online Pharmacy Market Sales by Geography (USD MN)
  • Global Market by Revenue
  • North America Market by Revenue
  • Europe Market by Revenue
  • Asia Pacific Market by Revenue
  • Latin America Market by Revenue
  • Middle East & Africa Market by Revenue
  • Recent Development in Industry
  • Top Company Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11219892

The global demand for Vulvovaginal Candidiasis Treatment Market is presumed to reach the market size of nearly USD 6.96 BN by 2030 from USD 4.2 BN in 2022 with a CAGR of 6.51% under the study period 2023 - 2030.

Vulvovaginal candidiasis treatment is a treatment for vaginal yeast infection, a common fungus infection. Itching, a burning feeling or discomfort during urine or intercourse, swelling, rash, and inflammation, are all signs of vaginal yeast infection. As diabetic cases rise and people use antibiotics more frequently, vulvovaginal candidiasis prevalence has grown. Antifungal medicines are typically recommended for the treatment of vaginal candidiasis.

MARKET DYNAMICS:

The market is foreseen to follow a growing trend with the increase in vulvovaginal candidiasis infections and the requirement for effective medicines to treat the condition. The significant increase in research and development, new drug approvals, and product launches are scaling up the demand for better treatment options, creating a profitable opportunity for the commercial growth of vulvovaginal candidiasis treatment. In addition, there will be a lot of opportunities for the treatment of vulvovaginal candidiasis over the anticipated time frame because of an increase in healthcare and government investments, development of the healthcare system, accessibility of medications, and significant technological developments in the pharmaceutical and biotechnology sectors. The market for vulvovaginal candidiasis treatment is estimated to be hampered due to lack of public awareness, expertise in employing new technologies, and high costs related to diagnostic and treatment methods.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of vulvovaginal candidiasis treatment. The growth and trends of vulvovaginal candidiasis treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the vulvovaginal candidiasis treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

  • Clotrimazole
  • Nystatin
  • Fluconazole
  • Ketoconazole
  • Terbinafine
  • Terconazole
  • Others

By Route Of Administration

  • Oral
  • Intravenous
  • Topical

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Vulvovaginal Candidiasis Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the vulvovaginal candidiasis treatment market include Astellas Pharma Inc., Mycovia Pharmaceuticals Inc., Bayer AG., Basilea Pharmaceutica Ltd., Scynexis Inc., Grupo Ferrer Internacional S.A., Pfizer Inc., Cadila Pharmaceuticals, Bristol-Myers Squibb Company. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . VULVOVAGINAL CANDIDIASIS TREATMENT - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Class
    • 3.7.2 Market Attractiveness Analysis By Route Of Administration
    • 3.7.3 Market Attractiveness Analysis By Distribution Channel
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

  • 5.1. Impact Analysis of Covid-19 Outbreak
    • 5.1.1. Direct Impact on Production
    • 5.1.2. Supply Chain and Market Disruption
    • 5.1.3. Financial Impact on Firms and Financial Markets
  • 5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
  • 5.3. Market: Pre V/S Post COVID-19
  • 5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
  • 5.5. COVID-19: Micro and Macro Factor Analysis

6 . GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET ANALYSIS BY DRUG CLASS

  • 6.1 Overview by Drug Class
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Drug Class
  • 6.4 Clotrimazole Historic and Forecast Sales by Regions
  • 6.5 Nystatin Historic and Forecast Sales by Regions
  • 6.6 Fluconazole Historic and Forecast Sales by Regions
  • 6.7 Ketoconazole Historic and Forecast Sales by Regions
  • 6.8 Terbinafine Historic and Forecast Sales by Regions
  • 6.9 Terconazole Historic and Forecast Sales by Regions
  • 6.10. Others Historic and Forecast Sales by Regions

7 . GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 7.1 Overview by Route Of Administration
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Route Of Administration
  • 7.4 Oral Historic and Forecast Sales by Regions
  • 7.5 Intravenous Historic and Forecast Sales by Regions
  • 7.6 Topical Historic and Forecast Sales by Regions

8 . GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET SALES ANALYSIS BY DISTRIBUTION CHANNEL

  • 8.1 Overview by Distribution Channel
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by Distribution Channel
  • 8.4 Hospital Pharmacy Historic and Forecast Sales by Regions
  • 8.5 Retail Pharmacy Historic and Forecast Sales by Regions
  • 8.6 Online Pharmacy Historic and Forecast Sales by Regions

9 . GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET SALES ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook Sales Analysis
  • 9.2. Introduction Sales Analysis
  • 9.3. North America Sales Analysis
    • 9.3.1. Overview, Historic and Forecast Sales Analysis
    • 9.3.2. North America By Segment Sales Analysis
    • 9.3.3. North America By Country Sales Analysis
    • 9.3.4. United State Sales Analysis
    • 9.3.5. Canada Sales Analysis
    • 9.3.6. Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1. Overview, Historic and Forecast Sales Analysis
    • 9.4.2. Europe by Segment Sales Analysis
    • 9.4.3. Europe by Country Sales Analysis
    • 9.4.4. United Kingdom Sales Analysis
    • 9.4.5. France Sales Analysis
    • 9.4.6. Germany Sales Analysis
    • 9.4.7. Italy Sales Analysis
    • 9.4.8. Russia Sales Analysis
    • 9.4.9. Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1. Overview, Historic and Forecast Sales Analysis
    • 9.5.2. Asia Pacific by Segment Sales Analysis
    • 9.5.3. Asia Pacific by Country Sales Analysis
    • 9.5.4. China Sales Analysis
    • 9.5.5. India Sales Analysis
    • 9.5.6. Japan Sales Analysis
    • 9.5.7. South Korea Sales Analysis
    • 9.5.8. Australia Sales Analysis
    • 9.5.9. Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1. Overview, Historic and Forecast Sales Analysis
    • 9.6.2. Latin America by Segment Sales Analysis
    • 9.6.3. Latin America by Country Sales Analysis
    • 9.6.4. Brazil Sales Analysis
    • 9.6.5. Argentina Sales Analysis
    • 9.6.6. Peru Sales Analysis
    • 9.6.7. Chile Sales Analysis
    • 9.6.8. Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1. Overview, Historic and Forecast Sales Analysis
    • 9.7.2. Middle East & Africa by Segment Sales Analysis
    • 9.7.3. Middle East & Africa by Country Sales Analysis
    • 9.7.4. Saudi Arabia Sales Analysis
    • 9.7.5. UAE Sales Analysis
    • 9.7.6. Israel Sales Analysis
    • 9.7.7. South Africa Sales Analysis
    • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE VULVOVAGINAL CANDIDIASIS TREATMENT COMPANIES

  • 10.1. Vulvovaginal Candidiasis Treatment Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11 . COMPANY PROFILES OF VULVOVAGINAL CANDIDIASIS TREATMENT INDUSTRY

  • 11.1. Top 10 Company Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Astellas Pharma Inc.
    • 11.3.1. Company Overview
    • 11.3.2. Company Revenue
    • 11.3.3. Products
    • 11.3.4. Recent Developments
  • 11.4. Mycovia Pharmaceuticals Inc.
    • 11.4.1. Company Overview
    • 11.4.2. Company Revenue
    • 11.4.3. Products
    • 11.4.4. Recent Developments
  • 11.5. Bayer AG.
    • 11.5.1. Company Overview
    • 11.5.2. Company Revenue
    • 11.5.3. Products
    • 11.5.4. Recent Developments
  • 11.6. Basilea Pharmaceutica Ltd.
    • 11.6.1. Company Overview
    • 11.6.2. Company Revenue
    • 11.6.3. Products
    • 11.6.4. Recent Developments
  • 11.7. Scynexis Inc.
    • 11.7.1. Company Overview
    • 11.7.2. Company Revenue
    • 11.7.3. Products
    • 11.7.4. Recent Developments
  • 11.8. Grupo Ferrer Internacional S.A.
    • 11.8.1. Company Overview
    • 11.8.2. Company Revenue
    • 11.8.3. Products
    • 11.8.4. Recent Developments
  • 11.9. Pfizer Inc.
    • 11.9.1. Company Overview
    • 11.9.2. Company Revenue
    • 11.9.3. Products
    • 11.9.4. Recent Developments
  • 11.10. Cadila Pharmaceuticals
    • 11.10.1. Company Overview
    • 11.10.2. Company Revenue
    • 11.10.3. Products
    • 11.10.4. Recent Developments
  • 11.11. Bristol-Myers Squibb Company
    • 11.11.1. Company Overview
    • 11.11.2. Company Revenue
    • 11.11.3. Products
    • 11.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies